Protocol Ledger

NCT04976634 · Phase II · ACTIVE NOT RECRUITING

Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

Interventional Phase II clinical trial protocol NCT04976634 sponsored by Merck & Co. in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-08-18 Enrollment: 730 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT04976634
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)730 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04976634
Protocol FieldVerified Registry Value
NCT IdentifierNCT04976634
Consolidated Lead SponsorMerck & Co.
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment730 participants (ESTIMATED)
Registered Start Date2021-08-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI